Pluristem Therapeutics, Inc. (PSTI): Price and Financial Metrics


Pluristem Therapeutics, Inc. (PSTI): $1.00

-0.03 (-2.91%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PSTI to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

PSTI Stock Price Chart Interactive Chart >

Price chart for PSTI

PSTI Price/Volume Stats

Current price $1.00 52-week high $3.45
Prev. close $1.03 52-week low $0.95
Day low $0.95 Volume 170,600
Day high $1.05 Avg. volume 715,259
50-day MA $1.27 Dividend yield N/A
200-day MA $1.87 Market Cap 32.35M

Pluristem Therapeutics, Inc. (PSTI) Company Bio


Pluristem Therapeutics Inc. operates as a bio-therapeutics company in Israel. The company focuses on the research, development, clinical trial, and manufacture of cell therapeutics products and related technologies for the treatment of various ischemic and inflammatory conditions. The company was founded in 2001 and is based in Haifa, Israel.


PSTI Latest News Stream


Event/Time News Detail
Loading, please wait...

PSTI Latest Social Stream


Loading social stream, please wait...

View Full PSTI Social Stream

Latest PSTI News From Around the Web

Below are the latest news stories about PLURISTEM THERAPEUTICS INC that investors may wish to consider to help them evaluate PSTI as an investment opportunity.

10 Biotech Penny Stocks with Growth Catalysts

In this article, we discuss 10 biotech penny stocks with growth catalysts. If you want to see some more stocks in this selection, check out 5 Biotech Penny Stocks with Growth Catalysts. According to Global Market Insights, the market for biotech in 2020 was valued at $497 billion, and it is forecasted to grow to […]

Yahoo | April 6, 2022

Pluristem and Tnuva to Ring Nasdaq Closing Bell in Honor of New Partnership

Closing Bell Ringing Ceremony Will Take Place on Monday, March 28 at 3:45 pm ET at Nasdaq MarketSite in Times Square, New York A live stream of the Nasdaq Closing Bell will be available at: https://livestream.com/accounts/27896496/events/10177910 HAIFA, Israel, March 28, 2022 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI) (“Pluristem”), a leading biotechnology company, and Tnuva Group (“Tnuva Group” or “Tnuva”), Israel’s largest food producer, today announced that Pl

Yahoo | March 28, 2022

Pluristem''s PLX-R18 Shows Meaningful Advantage Over Other Treatments In Transplant Patients

Pluristem Therapeutics Inc (NASDAQ: PSTI ) announced final results from its hematology Phase 1 study of intramuscular injections of PLX-R18 in subjects with incomplete hematopoietic recovery following hematopoietic cell transplantation (HCT). Data collated 12 months post-treatment with PLX-R18 demonstrate that PLX-R18 was well-tolerated with … Full story available on Benzinga.com

Benzinga | March 23, 2022

Pluristem PLX-R18 shows promise in blood cell recovery in cell transplant patients in trial

Pluristem Therapeutics (PSTI) reported final results from a phase 1 trial of intramuscular injections of PLX-R18 in patients with incomplete hematopoietic recovery following…

Seeking Alpha | March 23, 2022

Pluristem Releases PLX-R18 Hematology Phase I Study Results: Data Show Increase in All Blood Lines and Reduction in Blood Transfusions

Results show the potential in the use of PLX-R18 for meaningful advantage over other existing and proposed treatments in post hematopoietic cell transplantation (HCT) patients.PLX-R18 reduced mortality from 29% to 18%1 and was well-tolerated with a favorable safety profile.PLX-R18 was granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of graft failure and incomplete hematopoietic recovery following HCT and the prevention and treatment of acute radiat

Yahoo | March 23, 2022

Read More 'PSTI' Stories Here

PSTI Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year -32.89%
3-year -73.54%
5-year -93.46%
YTD N/A
2022 0.00%
2021 -79.35%
2020 79.44%
2019 -50.13%
2018 -42.75%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.792 seconds.